This Sources Sought opportunity from Department Of Veterans Affairs was posted on May 1, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
Blood Sample Protein Measurement Analysis
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The Department of Veterans Affairs (VA), through the Washington DC VA Medical Center (DC VAMC), is seeking sources for a prospective biospecimen collection and clinical data repository study focused on advanced prostate cancer among Veterans. This study addresses the critical need for validated circulating biomarkers that can better predict treatment response and early disease progression, surpassing current reliance on PSA kinetics and imaging. The contract involves processing approximately 120 coded frozen plasma aliquots collected longitudinally from roughly 24 study participants. The vendor is required to perform high-plex proteomic analysis using the SomaScan assay platform under CLIA certification, adhering to established VA biospecimen handling protocols, including storage and shipment at –80°C. The vendor will thaw, prepare samples according to standard operating procedures, conduct assays with quality control measures, and deliver standardized proteomic data files (ADAT format) and quality assurance documentation back to the VA. Unused specimens must be returned to the VA after analysis. All generated data and materials will be the exclusive property of the U.S. Government. This solicitation is a firm-fixed-price contract with a base performance period plus a one-year option. The primary place of performance for the assay work is the vendor’s facility, while final data delivery and acceptance will occur at the DC VAMC. The procurement emphasizes strict compliance with federal and VA information security policies, including data segregation, secure data destruction per NARA and VA directives, and adherence to Privacy Act and FOIA regulations. Organizational conflict of interest mitigation measures include subcontractor approval requirements and restrictions on use and disclosure of VA data. The solicitation is currently a sources sought notice with no pricing or evaluation criteria disclosed. Proposals must include a capability statement, summary of relevant experience, business information including UEI, and small business status if applicable. Submissions are to be made electronically by May 15, 2026, to the designated VA point of contact. The overall effort supports exploratory biomarker research aimed at informing future precision oncology strategies tailored to Veterans with advanced prostate cancer.
General Info
Agency
NAICS
Place of Performance
Washington, DC, 20422, USASet-Aside
Timeline
Submission Closed
Organization & Contact Information
Full Description
The Washington DC VA Medical Center (DC VAMC) is conducting a prospective biospecimen collection and clinical data repository study. Advanced prostate cancer remains a leading cause of cancer morbidity and mortality among Veterans, yet validated circulating biomarkers that predict treatment response or early disease progression are lacking. Current clinical decision-making relies primarily on PSA kinetics and radiographic imaging, which have well-recognized limitations in sensitivity and lead time. The goal of the research study is to generate reproducible, high-quality proteomic data from the study’s longitudinal plasma specimens so that the VA study team can conduct exploratory analyses linking circulating proteomic changes to clinical outcomes, ultimately informing future biomarker validation studies and precision oncology strategies for Veterans with advanced prostate cancer.
